Merck (BSP:MRCK34) Cyclically Adjusted Revenue per Share: R$15.34 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:MRCK34 Merck & Co Inc BSP:MRCK34
78 GF Score
Price R$83.39
GF Value R$75.58
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted Revenue per Share?

Merck BSP:MRCK34 +0.60% 78 Cyclically Adjusted Revenue per Share is R$15.34 as of Mar. 2026. GuruFocus rates BSP:MRCK34 with a GF Score™ of 78/100 and a GF Value™ of R$75.58 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck's adjusted revenue per share for the three months ended in Mar. 2026 was R$4.307. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$15.34 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck's average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck was 17.80% per year. The lowest was -2.50% per year. And the median was 3.40% per year.

As of today (2026-07-25), Merck's current stock price is R$83.39. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was R$15.34. Merck's Cyclically Adjusted PS Ratio of today is 5.44.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.67.


Merck  (BSP:MRCK34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=83.39/15.34
=5.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck Cyclically Adjusted Revenue per Share Related Terms


Merck Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted Revenue per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.24 12.38 12.06 16.24 15.63

Merck Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.53 14.94 14.90 15.63 15.34

BSP:MRCK34 vs AMGN, ABBV, GILD: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.


BSP:MRCK34
78GF Score
Merck & Co Inc BSP:MRCK34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.307/330.2130*330.2130
=4.307

Current CPI (Mar. 2026) = 330.2130.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.510 241.018 2.069
201609 1.538 241.428 2.104
201612 1.528 241.432 2.090
201703 1.333 243.801 1.805
201706 1.486 244.955 2.003
201709 1.483 246.819 1.984
201712 1.574 246.524 2.108
201803 1.518 249.554 2.009
201806 1.830 251.989 2.398
201809 2.070 252.439 2.708
201812 2.027 251.233 2.664
201903 1.995 254.202 2.592
201906 2.190 256.143 2.823
201909 2.482 256.759 3.192
201912 0.832 256.974 1.069
202003 2.891 258.115 3.699
202006 2.392 257.797 3.064
202009 2.907 260.280 3.688
202012 2.771 260.474 3.513
202103 2.946 264.877 3.673
202106 2.822 271.696 3.430
202109 3.423 274.310 4.121
202112 3.770 278.802 4.465
202203 3.899 287.504 4.478
202206 3.625 296.311 4.040
202209 3.857 296.808 4.291
202212 3.559 296.797 3.960
202303 3.697 301.836 4.045
202306 3.593 305.109 3.889
202309 3.870 307.789 4.152
202312 3.526 306.746 3.796
202403 3.860 312.332 4.081
202406 4.264 314.175 4.482
202409 4.538 315.301 4.753
202412 4.700 315.605 4.918
202503 4.416 319.799 4.560
202506 4.360 322.561 4.463
202509 4.636 324.800 4.713
202512 4.499 324.054 4.585
202603 4.307 330.213 4.307

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$15.34 mean?
Merck (BSP:MRCK34) has a Cyclically Adjusted Revenue per Share of R$15.34 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted Revenue per Share too high?
Merck's current Cyclically Adjusted Revenue per Share is R$15.34. Overall, Merck has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted Revenue per Share compare to AMGN and ABBV?
Merck's Cyclically Adjusted Revenue per Share of R$15.34 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted Revenue per Share is R$15.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (BSP:MRCK34) is currently considered Fairly Valued. The stock's GF Value™ is R$75.58, compared to a current price of R$83.39 — trading 10.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$15.34. Merck's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Merck (BSP:MRCK34), the current Cyclically Adjusted Revenue per Share is R$15.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (BSP:MRCK34) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of R$83.39 is trading 10.3% above its estimated GF Value™ of R$75.58. GuruFocus considers Merck to be Fairly Valued.

Key valuation signals for BSP:MRCK34:

  • Cyclically Adjusted Revenue per Share: R$15.34
  • GF Value™: R$75.58 vs. price of R$83.39 (10.3% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the BSP:MRCK34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
78GF Score

Get the complete analysis for BSP:MRCK34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$83.39
Price
R$75.58
GF Value